OUR STORY
Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
Ascelia Pharma company presentation May 2022
TOP STORIES
Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal
2022.04.11
TOP STORIES
Oncoral featured in the journal International Pharmaceutical Industry
2022.04.08
In the April edition of the International Pharmaceutical Industry Journal, you can read about the science and our work to improve the outcomes for gastric cancer patients through our innovative daily oral chemotherapy drug candidate, Oncoral.
“Improving outcomes for gastric cancer patients via a novel dose chemotherapy formulation, Oncoral”.
TOP STORIES
New market research shows strong support for Orviglance
2022.03.29
New independent market research shows that 84% of healthcare professionals will likely use Orviglance® for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function.
Read more about the results:
TOP STORIES
Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study
2022.03.11
Ascelia Pharma today announced that the last patient visit has been completed in the clinical study to evaluate the effect of liver impairment on the safety, pharmacokinetics and pharmacodynamics of the company’s lead drug candidate Orviglance®.
TOP STORIES
Orviglance featured in the journal International Clinical Trials
2022.03.03
In the February 2022 edition of the journal International Clinical Trials, you can read about our novel contrast agent Orviglance.
“A New Approach to Imaging Focal Liver Lesions in Patients With Reduced Kidney Function.”